LATEST UPDATES » Vol 23, No 06, June 2019 – Clinical trials — What's in a name?       » Study reveals mechanism behind ginger's warming effect on body       » China proposes major changes to pharmaceutical regulations       » Six plants native to Southeast Asia are promising cancer warriors       » Cancer cells are addicted to methionine       » World's first molecular swing      
Government-supported Chinese biotech revolution will have highest positive impact on global pharma industry in 2019
Chinese drug developers to compete with multinational drug companies, give rise to more innovation

China, with its reformed priority review and approval processes, is supporting biotech revolution in the country and thereby allowing domestic drug developers to compete with well-established multinational counterparts.

Against this backdrop, China’s rise will result in more innovation and have the highest positive impact on the pharmaceutical industry in 2019, says GlobalData, a data and analytics company.

According to GlobalData, the number of cancer patients is on the rise in China and nearly 10,000 diagnosed melanoma cases were recorded in 2017. As a result, the Chinese government is eager to provide better and more affordable cancer care to its citizens.

To capitalise on the opportunity, multinational pharma giants Bristol-Myers Squibb and Merck had already received approval for two programmed cell death-1 (PD-1) inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab) in China in June and July 2018, respectively.

Edit Kovalcsik, pharma analyst at GlobalData said, “Chinese drug developers are lining up their branded products ready to take on competition with Western companies, not only in China, but around the world.”

Recently, China’s National Medical Products Authority (NMPA) conditionally approved PD-1 checkpoint inhibitor Tuoyi (toripalimab) monoclonal antibody injection for the treatment of melanoma from Chinese biotech firm Shanghai Junshi Biosciences.

Kovalcsik added, “The product could be the first locally developed drug launching in China in competition with the already approved global market-leading Keytruda. The approval is an important turning point in the history of Chinese drug development, which is moving away from producing ‘me-too’ drugs aimed at the domestic market to independently develop brands that will compete with Western developers’ drugs.”

One such Chinese biopharmaceutical company looking to compete on a global scale is BeiGene, with its oncology candidates: Bruton’s tyrosine kinase (BTK) zanubrutinib and PD-1 inhibitor tislelizumab, both of which were granted priority review status in for patients with relapsed/refractory mantle cell lymphoma and classical Hodgkin’s lymphoma respectively.

Kovalcsik concluded, “The government-supported Chinese biotech revolution will bring forth many Chinese drug developers to compete with well-established multinational drug companies. Simultaneously, the massive untouched market holds opportunities for foreign investors. By increasing competition, China’s rise will impact the global pharmaceutical industry and as a result, it could give rise to more innovation.”

Source: GlobalData

Click here for the complete issue.

news Discover key nutraceutical trends in Asia Pacific
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
Asia Pacific Biotech News

APBN Editorial Calendar 2019
Taiwan Medical tourism
Marijuana as medicine — Legal marijuana will open up scientific research
Driven by curiosity
Career developments for researchers
What's cracking — Antibodies in ostrich eggs
Clinical trials — What's in a name?
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy